The authors of a controversial meeting abstract linking ivermectin to lower mortality from Covid-19 have retracted the study, saying that the work has been widely “misinterpreted” and might be leading to patient harm.
The abstract, “Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database,” was presented at the 2021 International Meeting on Emerging Diseases and Surveillance.
According to the researchers, from the University of Miami, Covid-19 patients who took ivermectin were about 70% less likely to die of the disease than those who took remdesivir.
Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
Not surprisingly, the poster received a significant amount of attention on social media – both from ivermectin partisans and skeptics. At the time, the researchers tried to distance themselves from any firm conclusions about the work, stressing that they were reporting an association and not necessarily a causal effect.
With the highest cost of idle hospital beds being in the intensive care (ICU), people talk as if whole sections of hospitals sit empty waiting for the day when they are needed. Occupancy in ICUs typically are close to full. If they are not the hospital closes more beds so that they remain near capacity.
